No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Danaher Corporation is a global enterprise that develops, produces, and sells a diverse range of specialized products and services tailored for the professional, healthcare, industrial, and commercial sectors. Its operations are organized into three primary divisions: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences division delivers cutting-edge tools and solutions such as mass spectrometers, flow cytometry systems, genomics platforms, laboratory automation, centrifuges, particle analysis equipment, microscopes, and consumables for genomics, alongside Gene and Cell Therapy offerings. It further provides advanced bioprocess technologies, associated consumables, and support services. This segment is also a key supplier of filtration, separation, and purification technologies. Its clientele spans pharmaceutical and biopharmaceutical firms, food and beverage producers, medical organizations, life sciences enterprises, academic institutions including universities and medical schools, research facilities, and diverse industrial manufacturers. The Diagnostics segment specializes in diagnostic solutions, encompassing chemistry, immunoassay, microbiology, and automation systems, in addition to products for hematology, molecular diagnostics, acute care, and pathology. This segment supplies clinical instruments, reagents, consumables, software platforms, and related services to healthcare providers such as hospitals, doctors' offices, reference laboratories, and other vital critical care environments. The Environmental & Applied Solutions division provides a comprehensive suite of instrumentation, consumables, software, services, and disinfection systems. These offerings are crucial for the analysis, treatment, and management of various water types—including ultra-pure, drinking, industrial, waste, groundwater, source water, and ocean water—across residential, commercial, industrial, and natural resource contexts. Furthermore, this segment delivers instruments, software, services, and consumables supporting color and appearance management, packaging design and quality control, packaging conversion, printing, marking, coding, and traceability for consumer, pharmaceutical, and industrial goods. Established in 1969, the company initially operated as Diversified Mortgage Investors, Inc. before adopting the name Danaher Corporation in 1984. Its corporate headquarters are situated in Washington, D.C.
www.danaher.comNo one on the platform currently holds DAP.DE.
No tracked institution reports a position in DAP.DE as of their last filing.
No one on the platform has traded DAP.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.9% | 8.1% | 7.6% | — | — | — |
| Rev. Growth % | 2.9% | 2.0% | ||||
| Profit Margin % | 14.7% | 19.1% | 17.1% | |||
| Free Cash Flow Margin % | 21.4% | 23.0% | 20.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $26.0B | +5.8% | $8.38 | $8.21–$8.54 | — | 1 |
| 2027 | $28.0B | +8.0% | $9.17 | $8.97–$9.34 | — | 1 |
| 2028 | $29.9B | +6.6% | $10.07 | $9.86–$10.26 | — | 1 |
| 2029 | $32.1B | +7.5% | $11.17 | $10.93–$11.38 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $1.62 | $1.70 | +4.9% |
| 2026-04-21 | $1.68 | $1.78 | +6.0% |
| 2026-01-28 | $1.84 | $1.90 | +3.3% |
| 2025-10-21 | $1.47 | $1.61 | +9.5% |
| 2025-07-22 | $1.40 | $1.53 | +9.3% |
| 2025-04-22 | $1.50 | $1.74 | +16.0% |
| 2025-01-29 | $2.08 | $2.07 | -0.5% |
| 2024-10-22 | $1.41 |
| $1.54 |
| +9.2% |
| $156.7B |
| — |
| PFE.DEPfizer Inc. | $23.86 | -0.81% | $136.0B | — |
| PFE.FPfizer Inc. | $23.89 | -0.69% | $136.2B | — |
Source: Financial Modeling Prep · peers by sector/industry